Jazz Pharmaceuticals (NASDAQ:JAZZ) EVP Neena Patil Sells 1,200 Shares

June 13, 2026 by InsiderTrades.com

Key Points

Jazz Pharmaceuticals EVP Neena Patil sold 1,200 shares on June 10 at an average price of $231.83, bringing in about $278,196. After the sale, she still held 51,549 shares valued at roughly $11.95 million.
The stock has been under pressure, falling 2.4% to $230.56 in Friday trading, though it remains near its 52-week high of $243.32 and well above its 52-week low of $105.00.
Investor sentiment is being weighed down by a key trial setback: Jazz said the Phase 3 LAGOON trial for Zepzelca missed its primary endpoint in second-line small cell lung cancer, raising uncertainty around one of its important oncology assets.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Get Free Report) EVP Neena Patil sold 1,200 shares of the firm's stock in a transaction that occurred on Wednesday, June 10th. The stock was sold at an average price of $231.83, for a total transaction of $278,196.00. Following the sale, the executive vice president directly owned 51,549 shares in the company, valued at approximately $11,950,604.67. The trade was a 2.27% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Jazz Pharmaceuticals Stock Down 2.4%

Zymeworks Offers Hope for More than Just Long-Term Investors

JAZZ stock opened at $230.56 on Friday. The company has a current ratio of 2.04, a quick ratio of 1.85 and a debt-to-equity ratio of 0.95. Jazz Pharmaceuticals PLC has a twelve month low of $105.00 and a twelve month high of $243.32. The company's 50 day moving average is $217.61 and its two-hundred day moving average is $188.84. The stock has a market cap of $14.48 billion, a P/E ratio of -11,522.24, a PEG ratio of 0.21 and a beta of 0.32.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last announced its earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 EPS for the quarter. The business had revenue of $1.07 billion for the quarter. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. Research analysts expect that Jazz Pharmaceuticals PLC will post 22.09 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Top Marijuana Stocks: Plenty of Investment Opportunities Abound (You're not Late to the Game)

A number of brokerages have recently commented on JAZZ. Sanford C. Bernstein reaffirmed a "market perform" rating on shares of Jazz Pharmaceuticals in a report on Tuesday. Robert W. Baird set a $252.00 target price on shares of Jazz Pharmaceuticals in a report on Wednesday, May 6th. Barclays lifted their target price on shares of Jazz Pharmaceuticals from $234.00 to $253.00 and gave the company an "overweight" rating in a report on Wednesday, May 27th. Truist Financial set a $256.00 target price on shares of Jazz Pharmaceuticals and gave the company a "buy" rating in a report on Tuesday. Finally, Wells Fargo & Company lifted their target price on shares of Jazz Pharmaceuticals from $250.00 to $265.00 and gave the company an "overweight" rating in a report on Wednesday, May 6th. Sixteen investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, Jazz Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average price target of $246.06.

Check Out Our Latest Research Report on Jazz Pharmaceuticals

Hedge Funds Weigh In On Jazz Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of JAZZ. Hilltop National Bank purchased a new stake in shares of Jazz Pharmaceuticals during the 4th quarter worth $36,000. LRI Investments LLC purchased a new stake in shares of Jazz Pharmaceuticals during the 4th quarter worth $38,000. Westpac Banking Corp purchased a new stake in shares of Jazz Pharmaceuticals during the 1st quarter worth $51,000. Leonteq Securities AG purchased a new stake in shares of Jazz Pharmaceuticals during the 4th quarter worth $50,000. Finally, Root Financial Partners LLC boosted its position in shares of Jazz Pharmaceuticals by 42.8% during the 1st quarter. Root Financial Partners LLC now owns 297 shares of the specialty pharmaceutical company's stock worth $56,000 after purchasing an additional 89 shares in the last quarter. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Jazz Pharmaceuticals

Here are the key news stories impacting Jazz Pharmaceuticals this week:

Negative Sentiment: Jazz Pharmaceuticals said the Phase 3 LAGOON trial for Zepzelca did not meet its primary endpoint of overall survival in second-line small cell lung cancer. Jazz Pharmaceuticals Provides Update on Zepzelca (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer
Negative Sentiment: Reuters reported the trial failure could put Zepzelca’s current regulatory status at risk, raising uncertainty around a key oncology asset. Jazz Pharmaceuticals lung cancer drug fails main trial goal
Negative Sentiment: Industry coverage from multiple outlets reinforced the setback, suggesting investor concern may persist until Jazz clarifies next steps for Zepzelca. Jazz Pharma announces late-stage trial setback for lung cancer therapy
Negative Sentiment: FiercePharma noted the latest twist in the Zepzelca saga, highlighting the importance of the drug to Jazz’s cancer franchise and the market’s negative reaction to the failure. In latest twist in Zepzelca saga, Jazz and PharmaMar lung cancer drug fails phase 3 test
Negative Sentiment: Separately, an SEC filing showed EVP Neena M. Patil sold 1,200 shares earlier this week, a small insider sale that may add to cautious sentiment. Jazz Pharmaceuticals PLC EVP Neena M. Patil sold shares
Neutral Sentiment: Some recent commentary still frames Jazz as a value stock with a “moderate buy” analyst consensus, but this is being overshadowed by the trial disappointment. Why Jazz Pharmaceuticals (JAZZ) is a Top Value Stock for the Long-Term

Jazz Pharmaceuticals Company Profile

(Get Free Report)

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company's research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz's product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.